Table 1 Patient demographics (N=23)

From: A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

Characteristics

Numbers

Age (years)

Previous chemotherapies

Gender

 Male

11

  

 Female

12

  

Primary cancer

 Bile duct cancer

 

51

3

 Breast cancer

 

56

5

 Breast cancer

 

67

2

 Breast cancer

 

41

6

 Colon cancer

 

71

4

 Colon cancer

 

56

3

 Hepatocellular carcinoma

 

62

1

 Leiomyosarcoma

 

69

2

 Medulloblastoma

 

40

8

 Non-small cell lung carcinoma

 

63

5

 Oesophageal carcinoma

 

49

2

 Oesophageal carcinoma

 

53

7

 Ovarian cancer

 

44

6

 Ovarian cancer

 

55

6

 Pancreatic carcinoma

 

62

2

 Parotid adenocarcinoma

 

66

1

 Penile carcinoma

 

63

5

 Prostate cancer

 

65

3

 Rectal cancer

 

64

5

 Rectal cancer

 

64

5

 Renal cancer

 

69

5

 Thyroid cancer

 

62

0

 Uterine cancer

 

54

6